Recovery characteristics following antagonism of vecuronium with edrophonium, neostigmine or pyridostigmine.
D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004491:Edrophonium / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009388:Neostigmine / Q000627:therapeutic use; D009469:Neuromuscular Junction / Q000187:drug effects*; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D011897:Random Allocation; D014673:Vecuronium Bromide / Q000037:antagonists & inhibitors*
D002800:Cholinesterase Inhibitors; D009388:Neostigmine; D004491:Edrophonium; D014673:Vecuronium Bromide; D011729:Pyridostigmine Bromide